#survival
Latest news and interesting information about survival.
Why does the brain choose junk food?
Psychotherapist Yelena Kunakovskaya explains why the brain chooses junk food. Ancient survival mechanisms and energy seeking.
Cogent Stock Price Target Raised to $55
Cogent Biosciences PEAK trial: combination therapy shows 45.6% response rate, 16.5 months PFS, FDA accepts NDA. H.C. Wainwright raises price target to $55.
Could GLP-1 drugs be oncology's next big opportunity?
New research suggests GLP-1 drugs may play a role in cancer prevention and treatment, opening a potential new frontier for these popular therapies.
Revolution Medicines Phase 3 Trial Results
Revolution Medicines announces positive Phase 3 trial results for daraxonrasib in pancreatic cancer, showing significant survival benefit.
Prostate cancer death risk cut by 20% with J&J drug
Johnson & Johnson's apalutamide reduces prostate cancer death risk by 20%, according to Phase 3 trial results.
Brenetafusp Shows Promise in Melanoma
Immunocore's brenetafusp showed 14.3-month median overall survival in Phase 1/2 melanoma trial, supporting Phase 3 development.
Cabometyx Cuts Neuroendocrine Tumor Risk
Exelixis announces Cabometyx reduces neuroendocrine tumor progression risk by 74% in CABINET trial. New data presented at ASCO.
Zelenskiy asks Trump for air defense
Zelenskiy asks Trump for air defense: Urgent call for Patriot systems and interceptors to counter Russian ballistic missile threats.
Junshi Biosciences completes phase III lung cancer study
Junshi Biosciences completes phase III lung cancer study. Toripalimab combination shows promising results in resectable stage II-III NSCLC.
Pfizer SWOT analysis: new drugs
Pfizer SWOT analysis: new drugs Tukysa and anti-obesity strategy to navigate patent cliff.
Summit Therapeutics Analysis: Cantor Fitzgerald Backs Overweight
Cantor Fitzgerald reiterates Overweight on Summit Therapeutics. HARMONi-3 trial miss and analyst views covered by Bond.az.
Trodelvy Gets EU Backing for Breast Cancer
Gilead's Trodelvy receives EU backing for triple-negative breast cancer. ASCENT-03 study shows 38% risk reduction.
Bernstein Initiates BioNTech Coverage with Concerns
Bernstein initiates BioNTech coverage with Market Perform rating and $96 target, citing pipeline concerns.
Immuneering stock jumps on pancreatic cancer trial data
Immuneering stock jumps 12.5% after promising pancreatic cancer trial results.
Kennedy backs away from CDC vaccine panel changes
U.S. Health Secretary Kennedy steps back from recent CDC vaccine panel reforms. New charter removes specific expertise requirements.
Strong solar flares recorded on the Sun
Strong solar flares recorded on the Sun. Solar Orbiter captured three flares. Destruction of sunspots reduces threat to Earth.
High Gas Prices Spur Americans to Improvise
High gas prices in the US force Americans to use public transit, work from home, and find creative solutions like toy cars.
Genentech to Present Breast Cancer Data at ASCO Meeting
Genentech will present breast cancer data on giredestrant and other drugs at the 2026 ASCO meeting.
US-Iran standoff: Risk of fresh conflict
The US-Iran standoff over the Strait of Hormuz and nuclear program risks a fresh conflict. Economic pressure mounts as negotiations stall.
Telix completes enrollment in glioblastoma therapy trial
Telix Pharmaceuticals completes patient enrollment for TLX101-Tx glioblastoma therapy trial.
BofA raises Candel price target to $9
BofA raises Candel price target to $9 after 39% improvement in prostate cancer survival data.
Mauritius leader: Urbanization is about survival
Mauritius President Dharambeer Gokhool emphasizes urbanization as survival. At WUF13, he supports Azerbaijan's projects.
Nqa Kor Minq: Baku becomes world capital during 13th Urban Forum
Nqa Kor Minq: Baku becomes world capital during the 13th Urban Forum. UN official highlights global urban crisis.
Mauritius first female president on gender equality
Mauritius' first female president Ameenah Gurib-Fakim emphasizes gender equality's role in urban development.
SK Hynix Set to Become 2nd Korean Firm with $1 Trillion Cap
SK Hynix is set to reach a $1 trillion market cap, becoming the second South Korean company to do so. KB Securities raised its price target to 3 million won and boosted DRAM/NAND price forecasts.
ImmunityBio secures exclusive U.S. rights to Tokyo BCG strain
ImmunityBio secures exclusive U.S. rights to the Tokyo BCG strain for bladder cancer treatment. SWOG S1602 trial shows promising results.
Dead whale may be "Timmy"?
A dead whale found in the North Sea may be "Timmy". No GPS transmitter found; tissue sample sent to Germany for analysis.
Regeneron melanoma drug trial misses primary endpoint
Regeneron's melanoma drug trial fails primary endpoint: fianlimab+cemiplimab combination did not significantly improve progression-free survival vs pembrolizumab.
US cancer centers rush for Revolution drug
U.S. cancer centers are rushing to enroll patients in an early access program for Revolution Medicines' promising pancreatic cancer drug.
Haramball: The Art of Survival in Football
Explore haramball, the defensive football tactic from Sun Tzu to Guardiola, with analysis of Arsenal vs Atletico Madrid match.
...